全身体与常规PET/CT在非小细胞肺癌淋巴结分期中的诊断准确性
这项前瞻性单中心交叉头对头研究纳入48例非小细胞肺癌患者,同日行[18F]FDG全身体(TB)与短轴向视野(SAFOV)PET/CT,其中28例共700个淋巴结站可对照复合参考标准。TB与SAFOV PET/CT对基于患者的N分期均显示高诊断准确性,TB的敏感性和阳性预测值略高但差异无统计学意义,TB PET/CT的N分期错误率更低、半定量阈值更低。
要点
- TB与SAFOV PET/CT基于患者的N分期敏感性和特异性均较高。
- TB的阳性预测值高于SAFOV但差异无统计学意义(p=0.08)。
- TB PET/CT的N分期错误病例数少于SAFOV(1例 vs 6例)。
核心结论
- TB与SAFOV PET/CT在非小细胞肺癌患者N分期中均显示高诊断准确性指数。
- TB PET/CT的敏感性和阳性预测值较SAFOV PET/CT略高,但无统计学显著性。
- TB PET/CT的N分期错误率更低,检测阳性纵隔淋巴结的半定量阈值更低。
- 因此TB PET/CT在检测非小细胞肺癌患者小而[18F]FDG摄取低的纵隔淋巴结转移方面可能具有优势。
研究设计与样本
- 前瞻性单中心交叉头对头比较研究,48例因分期或再分期转诊的非小细胞肺癌患者同日接受[18F]FDG TB与SAFOV PET/CT。
- 28例患者的700个淋巴结站(1R/L、2R/L、3a/p、4R/L、5、6、7、8R/L、9R/L、10-14R/L)可与复合参考标准(组织病理学对照、局部或全身治疗后的影像)进行对照。
- 以SUVmax、肿瘤-本底比(TBR)、代谢肿瘤体积(MTV)和总病灶糖酵解(TLG)对淋巴结进行半定量分析,得出各扫描仪的阈值。
主要发现
- 基于患者的N分期,TB的敏感性和特异性分别为86.0%(CI:77.0-95.0%)和98.3%(CI:97.3-99.3%)。
- SAFOV PET的敏感性和特异性分别为77.2%(CI:66.3-88.1%)和97.4%(CI:96.1-98.6%)。
- TB的阳性预测值为81.7%(CI:71.9-91.5%),SAFOV PET为72.1%(CI:60.9-83.4%),差异无统计学意义(p=0.08)。
- TB的阴性预测值为98.6%(CI:97.9-99.6%),SAFOV PET/CT为98.0%(CI:96.9-99.1%),两者相当。
- SAFOV影响6例的NSCLC N分期,TB PET/CT仅影响1例;两种扫描仪检测真阳性病灶的SUVmax阈值均为3.0,TB的TBR、MTV和TLG阈值低于SAFOV(TBR:1.2 vs 1.7,MTV:0.5 ml vs 1.0 ml,TLG:1.0 ml vs 3.0 ml)。
关键数值与推荐
- TB PET/CT:敏感性86.0%(CI:77.0-95.0%),特异性98.3%(CI:97.3-99.3%),阳性预测值81.7%(CI:71.9-91.5%),阴性预测值98.6%(CI:97.9-99.6%)。
- SAFOV PET/CT:敏感性77.2%(CI:66.3-88.1%),特异性97.4%(CI:96.1-98.6%),阳性预测值72.1%(CI:60.9-83.4%),阴性预测值98.0%(CI:96.9-99.1%)。
- 两种扫描仪检测真阳性病灶的SUVmax阈值均为3.0。
- TB较SAFOV的TBR阈值为1.2 vs 1.7,MTV阈值为0.5 ml vs 1.0 ml,TLG阈值为1.0 ml vs 3.0 ml。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Our aim was to characterize the diagnostic accuracy indices for nodal (N)-staging with [18F]FDG Total-Body (TB) and short-axial field-of-view (SAFOV) PET/CT in non-small cell lung cancer (NSCLC) patients referred for staging or restaging. METHODS: In this prospective single center cross-over head-to-head comparative study 48 patients underwent [18F]FDG TB and SAFOV PET/CT on the same day. In total 700 lymph node levels (1R/L, 2R/L, 3a/p, 4R/L, 5, 6, 7, 8R/L, 9R/L, 10-14R/L) of 28 patients could be correlated to a composite reference standard (histopathological correlation, imaging after localized or systemic treatment), which allowed determination of true positive (TP), false positive (FP), true negative (TN) and false negative (FN) lesions. Lymph nodes were characterized semi-quantitatively by maximum standardized uptake value (SUVmax), tumor-to-background ratio (TBR), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) leading to threshold for each scanner. RESULTS: TB and SAFOV PET/CT showed high diagnostic accuracy indices for patient-based N-staging. Sensitivity and specificity were 86.0% (CI: 77.0-95.0%) and 98.3% (CI: 97.3-99.3%) for TB; 77.2% (CI: 66.3-88.1%) and 97.4% (CI: 96.1-98.6%) for SAFOV PET. Positive predictive value was higher for TB (81.7%, CI: 71.9-91.5%) compared to SAFOV PET (72.1%, CI: 60.9-83.4%). However, this finding was not statistically significant (p = 0.08). Negative predictive values for TB (98.6%, CI: 97.9-99.6%) and SAFOV PET/CT (98.0%, CI: 96.9-99.1%) were comparable. Overall, NSCLC N-staging was affected in six cases on SAFOV and only in one case on TB PET/CT. Semi-quantitative analysis revealed a threshold of SUVmax 3.0 to detect TP lesions on both scanners. However, TBR, MTV and TLG thresholds were lower on TB compared to SAFOV PET (TBR: 1.2 vs. 1.7, MTV: 0.5 ml vs. 1.0 ml and TLG: 1.0 ml vs. 3.0 ml). CONCLUSION: TB and SAFOV PET/CT showed high diagnostic accuracy indices for N-staging in NSCLC patients. Sensitivity and PPV on TB PET/CT were slightly higher, compared to SAFOV PET/CT without statistical significance. However, TB PET/CT showed lower rate of incorrect N-staging and lower semi-quantitative thresholds for the detection positive mediastinal lymph nodes. Therefore, TB PET/CT might be advantageous in detecting small and low [18F]FDG-avidity mediastinal lymph node metastases in NSCLC patients.
引用
- Mingels C, Madani MH, Sen F, et al. Diagnostic accuracy in NSCLC lymph node staging with Total-Body and conventional PET/CT. Eur J Nucl Med Mol Imaging. 2025. PMID: 40113643. doi:10.1007/s00259-025-07177-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。